MONARCH™ – BiotechReality – Information Intelligence System for Biopharma

Johnson & Johnson MedTech has announced the results of a novel clinical study from the TARGET study, assessing the MONARCH Platform for robotically assisted bronchoscopy. The study, published in the CHEST Journal, is the largest multi-center prospective trial of this type to be conducted so far. The TARGET (Transbronchial Biopsy Assisted by Robotic Guidance in the Evaluation of Tumors in the Lung) trial recruited 679 patients at 21 sites within the United States, Canada, and Hong Kong. Aimed at evaluating the safety, navigation success, and diagnostic yield of the MONARCH Platform in a real-world environment, the trial followed subjects for at least one year. Key Findings Navigation Success: The MONARCH Platform had a navigation success of reaching targeted lung nodules in 98.7% of instances. Diagnostic Yield: Diagnostic yield was reported at 83.2% according to the study, which reflects the platform's success in collecting tissue samples for diagnosis. Safety Profile: The safety outcomes were on par with those from non-robotic bronchoscopy methods, as no novel safety issues arose. MONARCHTM Platform The MONARCH Platform is the world's first robotically assisted bronchoscopy system for creating minimally invasive access to the airways in order to biopsy suspicious lung nodules. It counteracts the inherent difficulty of accessing lesions in the periphery of the lung. In addition to its diagnostic features, the platform has the potential to speed the patient care pathway, allowing care teams to facilitate patients into treatment an average of three weeks sooner. Source: Johnson & Johnson Last Modified:

Tag: MONARCH™

Johnson & Johnson MedTech Reports Strong Clinical Outcomes for MONARCH™ Robotic Bronchoscopy in Largest Study to Date

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment